Program
EvlaBio’s lead asset is an anti-FGFR4/FGF23 monoclonal Antibody (4/23-mAb) that selectively binds to FGFR4, and prevents the interaction of Fibroblast Growth Factor 23 (FGF23) with this receptor.
As 4/23-mAb clearly differentiates from existing drugs, it will be the first hemodynamically neutral drug with first in class and first in indication potential being complementary to, or synergistic with, several marketed drugs in this field.
Left Ventricular Hypertrophy (LVH) is a major cause of death and mortality in patients suffering from CKD. Up to 80% of patients with End Stage Renal Disease (ESRD) are affected by LVH, and the severity of LVH directly correlates with FGF23 serum levels. Furthermore, elevated FGF23 levels are independently associated with LVH in large and racially diverse patient cohorts. Therefore we are convinced that 4/23-mAb has the potential to prevent cardiac remodeling in patients with LVH in the setting of CKD.
Anti-FGFR4/FGF23
(Pre)Clinical data strongly indicates that FGFR4/FGF23 overdrive in chronic kidney disease (CKD) leads to left ventricular hypertrophy (LVH). In the 5/6 nephrectomy model in rats (relevant animal model for LVH/CKD) it could be shown that the selective blockage of FGFR4 effecively prevents the emergence of FGF23 driven LVH in CKD.